ERBB2 and breast cancer: The lack of expression of ER, PR, and HER2 characterizes the triple-negative breast cancer (TNBC) subtype, which accounts for approximately 15% of all BC cases[18], and it is the most aggressive subtype with the poorer outcomes[19].